| Fc receptor but not complement binding is important in antibody protection against HIV AJ Hessell, L Hangartner, M Hunter, CEG Havenith, FJ Beurskens, ... Nature 449 (7158), 101-104, 2007 | 1055 | 2007 |
| Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies … GD Tomaras, NL Yates, P Liu, L Qin, GG Fouda, LL Chavez, AC Decamp, ... Journal of virology 82 (24), 12449-12463, 2008 | 838 | 2008 |
| The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response RH Haubrich, SJ Little, JS Currier, DN Forthal, CA Kemper, GN Beall, ... Aids 13 (9), 1099-1107, 1999 | 689 | 1999 |
| Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers AJ Hessell, EG Rakasz, P Poignard, L Hangartner, G Landucci, ... PLoS pathogens 5 (5), e1000433, 2009 | 620 | 2009 |
| Prevention and treatment of monkeypox JG Rizk, G Lippi, BM Henry, DN Forthal, Y Rizk Drugs 82 (9), 957-963, 2022 | 564 | 2022 |
| Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys DH Barouch, J Liu, H Li, LF Maxfield, P Abbink, DM Lynch, MJ Iampietro, ... Nature 482 (7383), 89-93, 2012 | 525 | 2012 |
| Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys J Liu, KL O’Brien, DM Lynch, NL Simmons, A La Porte, AM Riggs, ... Nature 457 (7225), 87-91, 2009 | 523 | 2009 |
| Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both DV Havlir, MP Dubé, FR Sattler, DN Forthal, CA Kemper, MW Dunne, ... New England Journal of Medicine 335 (6), 392-398, 1996 | 428 | 1996 |
| Functions of antibodies DN Forthal Microbiology spectrum 2 (4), 10.1128/microbiolspec. aid-0019-2014, 2014 | 413 | 2014 |
| Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal … AJ Hessell, EG Rakasz, DM Tehrani, M Huber, KL Weisgrau, G Landucci, ... Journal of virology 84 (3), 1302-1313, 2010 | 402 | 2010 |
| Pharmaco-immunomodulatory therapy in COVID-19 JG Rizk, K Kalantar-Zadeh, MR Mehra, CJ Lavie, Y Rizk, DN Forthal Drugs 80, 1267-1292, 2020 | 341 | 2020 |
| Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells DN Forthal, G Landucci, ES Daar Journal of virology 75 (15), 6953-6961, 2001 | 297 | 2001 |
| Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS RA Larsen, SA Bozzette, BE Jones, D Haghighat, MA Leal, D Forthal, ... Clinical Infectious Diseases 19 (4), 741-745, 1994 | 252 | 1994 |
| Early outpatient treatment for Covid-19 with convalescent plasma DJ Sullivan, KA Gebo, S Shoham, EM Bloch, B Lau, AG Shenoy, ... New England Journal of Medicine 386 (18), 1700-1711, 2022 | 233 | 2022 |
| Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate DN Forthal, PB Gilbert, G Landucci, T Phan The Journal of Immunology 178 (10), 6596-6603, 2007 | 233 | 2007 |
| Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition M Vaccari, SN Gordon, S Fourati, L Schifanella, NPM Liyanage, ... Nature medicine 22 (7), 762-770, 2016 | 214 | 2016 |
| The prevalence of infection with human immunodeficiency virus over a 10-year period in rural Zaire N Nzilambi, KM De Cock, DN Forthal, HE Francis, RW Ryder, I Malebe, ... New England Journal of Medicine 318 (5), 276-279, 1988 | 208 | 1988 |
| Fc receptor-mediated antiviral antibodies DN Forthal, C Moog Current opinion in HIV and AIDS 4 (5), 388-393, 2009 | 204 | 2009 |
| Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12 DN Forthal, JS Gach, G Landucci, J Jez, R Strasser, R Kunert, ... The Journal of Immunology 185 (11), 6876-6882, 2010 | 171 | 2010 |
| Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques CT Ng, JP Jaworski, P Jayaraman, WF Sutton, P Delio, LR Kuller, ... Nature medicine 16 (10), 1117-1119, 2010 | 166 | 2010 |
